Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate

Srivastava, Tarak; Dai, Hongying; Haney, Connie; Alon, Uri

doi:10.1002/jbmr.290

Cited by 14 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…86 Hypocalcaemia/hypophosphatemia Bisphosphonate-induced hypocalcaemia occurs due to osteoclast inhibition of bone resorption. Contributing factors are vitamin D deficiency, 86 advanced renal disease, prolonged glucocorticoid use and subclinical hypoparathyroidism. Severe symptomatic hypocalcaemia is rare.…”

Section: Evidencementioning

confidence: 99%

Consensus guidelines on the use of bisphosphonate therapy in children and adolescents

Simm

Biggin

Zacharin

et al. 2018

J Paediatrics Child Health

125

118

View full text Add to dashboard Cite

Bisphosphonate therapy is the mainstay of pharmacological intervention in young people with skeletal fragility. The evidence of its use in a variety of conditions remains limited despite over three decades of clinical experience. On behalf of the Australasian Paediatric Endocrine Group, this evidence-based consensus guideline presents recommendations and discusses the graded evidence (using the GRADE system) for these recommendations. Primary bone fragility disorders such as osteogenesis imperfecta are considered separately from osteoporosis secondary to other clinical conditions (such as cerebral palsy, Duchenne muscular dystrophy). The use of bisphosphonates in non-fragility conditions, such as fibrous dysplasia, avascular necrosis, bone cysts and hypercalcaemia, is also discussed. While these guidelines provide an evidence-based approach where possible, further research is required in all clinical applications in order to strengthen the recommendations made.

show abstract

Section: Evidencementioning

confidence: 99%

Consensus guidelines on the use of bisphosphonate therapy in children and adolescents

Simm

Biggin

Zacharin

et al. 2018

J Paediatrics Child Health

125

118

View full text Add to dashboard Cite

show abstract

“…The cause(s) of the acute side effects are not clearly defined. Some studies have shown that these symptoms may be caused by a low vitamin D status, defined as serum 25-hydroxyvitamin D (25-OH-D) levels <30 ng/ml [74,75]. …”

Section: Adverse Effects Of Bisphosphonates In Pediatric Patientsmentioning

confidence: 99%

The Use of Bisphosphonates in Pediatrics

Baroncelli

Bertelloni

2014

Horm Res Paediatr

View full text Add to dashboard Cite

Bisphosphonates are widely used for the prevention and treatment of osteoporosis in adulthood. In the last years, bisphosphonates have been increasingly used in pediatric patients for the treatment of a growing number of disorders associated with osteoporosis, resistant hypercalcemia or heterotopic calcifications. The use of bisphosphonates in pediatric patients has been proven safe; however, the risk of potential severe consequences into adulthood should be kept in mind. Well-defined criteria for bisphosphonates treatment in pediatric patients are not specified, therefore an accurate selection of patients who could benefit from bisphosphonates is mandatory. A strict follow-up of pediatric patients receiving long-term bisphosphonate therapy is strongly recommended. The purpose of this mini review is to provide a summary of current knowledge on some main general aspects of the structure, mechanisms of action, pharmacokinetics, and bioavailability of bisphosphonates, and to focus on the latest advances of bisphosphonate treatment in pediatric patients. Particular attention has been paid to the common and potential adverse effects of bisphosphonate treatment, and some suggestions concerning the clinical approach and general measures for bisphosphonate treatment in pediatric patients are reported.

show abstract

“…Vitamin D homeostasis and adequacy of calcium intake should be monitored, as any insufficiency can impair the skeletal response to bisphosphonate therapy and may increase the likelihood of an adverse event, e.g. an acute-phase reaction [78] or hypocalcaemia.…”

Section: Monitoringmentioning

confidence: 99%

Primary Osteoporosis

Arundel¹,

Bishop²

2015

Calcium and Bone Disorders in Children and Adolescents

View full text Add to dashboard Cite

Primary osteoporosis in childhood encompasses a range of bone fragility conditions that typically have a genetic origin. Understanding of the pathophysiology and genetics of primary osteoporosis has increased dramatically over the past 10 years. The clinical manifestations and consequences of the disease range from mild to severe, with the degree of growth retardation and bony deformity reflecting the severity and the underlying pathology. In children, primary osteoporosis is most commonly caused by one of the forms of osteogenesis imperfecta, which comprises a group of disorders characterised by abnormalities in type I collagen synthesis or processing. Diagnosis of any primary osteoporotic condition depends on the clinical history and examination but may be supported by other investigations, including various imaging techniques, histology and genetic analyses. Good management requires a multidisciplinary approach involving paediatricians, surgeons and allied health professionals, amongst others. Bisphosphonate therapy has revolutionised the approach to management and has positively modified outcomes for many children and their families. Physiotherapy and occupational therapy are the keys to optimising independence in mobility and daily living. Surgery is required in many severe cases to straighten limbs or stabilise the spine. Bisphosphonates remain the mainstay of medical treatment, but there are a number of alternative therapeutic agents under investigation that may further improve management of primary osteoporosis in children over the coming years.

show abstract

Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate

Cited by 14 publications

References 5 publications

Consensus guidelines on the use of bisphosphonate therapy in children and adolescents

Consensus guidelines on the use of bisphosphonate therapy in children and adolescents

The Use of Bisphosphonates in Pediatrics

Primary Osteoporosis

Contact Info

Product

Resources

About